Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).
Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM. Peterson LM, et al. Among authors: link jm. Mol Imaging Biol. 2014 Jun;16(3):431-40. doi: 10.1007/s11307-013-0699-7. Epub 2013 Oct 30. Mol Imaging Biol. 2014. PMID: 24170452 Free PMC article. Clinical Trial.
18F-Fluoroestradiol.
Sundararajan L, Linden HM, Link JM, Krohn KA, Mankoff DA. Sundararajan L, et al. Among authors: link jm. Semin Nucl Med. 2007 Nov;37(6):470-6. doi: 10.1053/j.semnuclmed.2007.08.003. Semin Nucl Med. 2007. PMID: 17920354 Review.
NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.
Spence AM, Muzi M, Link JM, O'Sullivan F, Eary JF, Hoffman JM, Shankar LK, Krohn KA. Spence AM, et al. Among authors: link jm. Mol Imaging Biol. 2009 Sep-Oct;11(5):343-55. doi: 10.1007/s11307-009-0215-2. Epub 2009 Mar 27. Mol Imaging Biol. 2009. PMID: 19326172 Free PMC article.
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Linden HM, Kurland BF, Peterson LM, Schubert EK, Gralow JR, Specht JM, Ellis GK, Lawton TJ, Livingston RB, Petra PH, Link JM, Krohn KA, Mankoff DA. Linden HM, et al. Among authors: link jm. Clin Cancer Res. 2011 Jul 15;17(14):4799-805. doi: 10.1158/1078-0432.CCR-10-3321. Epub 2011 Jul 12. Clin Cancer Res. 2011. PMID: 21750198 Free PMC article.
161 results